Successful treatment of chronic knee pain following localization by a sigma-1 receptor radioligand and PET/MRI: a case report

Background: The ability to accurately diagnose and objectively localize pain generators in chronic pain sufferers remains a major clinical challenge since assessment relies on subjective patient complaints and relatively non-specific diagnostic tools. Developments in clinical molecular imaging, including advances in imaging technology and radiotracer design, have afforded the opportunity to identify tissues involved in pain generation based on their pro-nociceptive condition. The sigma-1 receptor (S1R) is a pro-nociceptive receptor upregulated in painful, inflamed tissues, and it can be imaged using the highly specific radioligand 18F-FTC-146 with PET.

Case presentation: A 50-year-old woman with a 7-year history of refractory, left-knee pain of unknown origin was referred to our pain management team. Over the past several years, she had undergone multiple treatments, including a lateral retinacular release, radiofrequency ablation of a paratellar nerve, and physical therapy. While certain treatments provided partial relief, her pain would inevitably return to its original state. Using simultaneous positron emission tomography/magnetic resonance imaging (PET/MRI) with the novel radiotracer 18F-FTC-146, imaging showed increased focal uptake of 18F-FTC-146 in the intercondylar notch, corresponding to an irregular but equivocal lesion identified in the simultaneously acquired MRI. These imaging results prompted surgical removal of the lesion, which upon resection was identified as an inflamed, intraarticular synovial lipoma. Removal of the lesion relieved the patient’s pain, and to date the pain has not recurred.

Conclusion: We present a case of chronic, debilitating knee pain that resolved with surgery following identification of the pathology with a novel clinical molecular imaging approach that detects chronic pain generators at the molecular and cellular level. This approach has the potential to identify and localize pain-associated pathology in a variety of chronic pain syndromes.

Keywords: PET/MRI, sigma-1 receptor, chronic pain, knee pain, molecular imaging, intraarticular synovial lipoma, 18F-FTC-146

Background

Accurate and objective identification of peripheral pain generators remains a significant clinical challenge in the management of individuals suffering from pain. The sigma-1 receptor (S1R), an inter-organelle signal modulator located predominantly in the endoplasmic reticulum membrane, is widely distributed in the central nervous system and in peripheral organs and is associated with various neurological diseases, including neuropathic pain.1,2 Increased expression of S1Rs is thought to modulate chronic pain by contributing to hypersensitivity and sensitization of the central nervous system.1

The PET radioligand, 18F-FTC-146 (6-(3-[18F]fluoropropyl)-3-(2-(azepan-1-yl)ethyl)benzo[d]thiazol-2(3 hours)-one), is a highly specific S1R antagonist that has been shown in preclinical experiments to bind specifically to the S1R and can therefore serve
as a tool for visualizing these receptors in vivo. Use of this tracer in conjunction with PET/MRI has identified sites of nerve injury in a rat neuropathic pain model, since increased S1R is present at the site of nerve injury. In addition, local administration of the non-radioactive form of [18F]-FTC-146 blocks S1Rs in neuromas of rats, resulting in pain relief. For this reason and from similar results shown by others, S1R antagonists represent a promising therapy for chronic pain.

The biodistribution of clinical-grade [18F]-FTC-146 is being evaluated in both healthy volunteers and patients with chronic pain (chronic sciatica and complex regional pain syndrome) as part of our first-in-human clinical trial of this novel radioligand (ClinicalTrials.gov identifier: NCT02753101). In healthy, asymptomatic volunteers, normal physiologic uptake of this radiotracer is observed in S1R-rich brain regions and specific peripheral organs, such as the pancreas and the spleen. In this report, we describe one of the patients from this clinical trial: a woman whose pain of 7 years resolved following the surgical removal of an intraarticular lipoma that showed high uptake of the S1R-specific radiotracer [18F]-FTC-146 on simultaneous PET/MRI.

### Case presentation

A 50-year-old woman presented to our nerve clinic with left-knee pain, which had begun 7 years previously with no apparent inciting event. She described the pain as sharp, at times stabbing, and radiating down the lateral aspect of her leg to her foot. She was unable to flex the knee beyond 60° without increased pain. She also described extreme difficulty in ambulating, standing up from a seated position, walking on grass, and going down stairs.

Shortly after the initial onset of the pain, the patient had undergone common peroneal nerve decompression. This had provided initial relief of her symptoms, but the pain returned. Injections with lidocaine and cortisone provided only slight relief, and injection with triamcinolone into the knee caused an increase in pain. She referred herself to a spine center for chronic pain and controls. The study protocol was approved by the Stanford University Institutional Review Board, and all participants provided written informed consent that included permission to publish details and images. The scan revealed focal increased uptake of the radiotracer in the intercondylar region of the left knee (Figure 1A, B). MRI showed an irregular, mass-like but equivocal lesion of intermediate density and T2-weighted images, appearing to represent a complex ganglion cyst or localized pigmented villonodular synovitis. Interestingly, there was no increased [18F]-FTC-146 uptake at the scarring around the common peroneal nerve, where radiofrequency ablation had been performed. While this lesion had been present in MRIs obtained in previous years (Figure 1C, D), it had not been noticed or commented upon.

The patient underwent arthroscopic removal of the intraarticular mass. During surgery, an area of inflammation was seen just posterior to the posterior cruciate ligament, matching the MRI. Biopsy showed mature adipose tissue with synovial lining, revealing the mass to be an intraarticular synovial lipoma (Figure 2).

In the weeks following surgery, her pain was well controlled and she was no longer taking narcotic pain medications. She went to physical therapy to improve strength and range of motion. At 1-year follow up, she had discontinued...
all medications and was completely free of pain. Upon physical examination, the site of surgery had healed well and she achieved full extension and flexion to 130°. MRI was performed and showed no evidence of a residual or recurrent mass.

**Conclusion**

We present a case of a woman whose chronic knee pain was resolved by removal of an intraarticular synovial lipoma, which had shown increased uptake of the novel, S1R-specific radioligand 18F-FTC-146 on simultaneous PET/MRI. The patient had previously undergone a variety of unsuccessful orthopedic surgeries and denervating interventions. Intraarticular synovial lipoma is rare in the knee; most cases involve the fat pad areas, rather than the intercondylar notch. Symptoms of intraarticular synovial lipoma are vague and depend on the size of the mass. If present, pain is thought to be

---

**Figure 1** PET/MRI and MRI of the left knee.

**Notes:** Axial (A) and coronal (B) PET/MRI show high uptake of 18F-FTC-146 in the intercondylar notch (red arrows: maximum standardized uptake value = 2.04). By comparison, the intercondylar notch of the right knee is normal (white arrow: maximum standardized uptake value = 0.17). MRI shows small joint effusion, with no synovitis, and an amorphous, mass-like in the intercondylar notch, initially presumed to be a ganglion cyst or localized pigmented villonodular synovitis/fibrous lesion. Sagittal (C) and coronal (D) MRI (T2-weighted with fat saturation) of the left knee, acquired approximately 3 years before PET/MRI study, show abnormal high-signal amorphous, mass-like but equivocal lesion in the intercondylar notch (white arrows). This had been overlooked or regarded as clinically insignificant.
caused by impingement or entrapment of the mass.6 The pain in this case was most likely secondary to the lipoma being a vascularized, space-occupying lesion caught between cruciate ligaments. Symptoms mimicking peroneal neuropathy, as in the present case, have not been reported in the literature. The lack of radiotracer uptake in the scar suggested that the common peroneal nerve, which had been suspected as the cause of pain, was most likely not the pain generator.

The high uptake of the tracer may be rationalized by the known presence of the free nerve endings in the synovium, and the presence of S1R on nerves and inflammatory cells.7 As S1Rs are associated with inflammatory processes that facilitate modulation of calcium ion channels,8,9 we hypothesize there may have been mechanical irritation of this mass with subsequent inflammation and increased expression of S1Rs in the synovial lipoma of the patient’s knee. This likely became a debilitating inflammatory pain generator that was ultimately detected by PET via increased uptake of the S1R-targeting radiotracer. While validity of this hypothesis is limited by the lack of immunohistological evidence showing S1R in the mass, the removal of the mass resulted in complete pain relief.

This case illustrates the promising application of 18F-FTC-146 PET/MRI as an improvement over MRI alone as an imaging modality for detecting pain generators. The ability to characterize painful or inflammatory pathology according to increased S1R density may prove to be an important clinical imaging method to objectively identify pain generators. The ongoing clinical investigation will be helpful in validating this process.

**Acknowledgments**

The authors would like to thank Jun Park (radiochemist) for synthesizing the radiotracer, Dawn Holley and Harsh Gandhi (PET/MRI technologists) for acquiring the images, and the PET/MRI Metabolic Service Center for its support. This study is funded in part by GE Healthcare and the Ben and Catherine Ivy Foundation.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**

1. Zamanillo D, Romero L, Merlos M, Vela JM. Sigma 1 receptor: a new therapeutic target for pain. *Eur J Pharmacol*. 2013;716(1-3):78–93.
2. Shen B, Behera D, James ML, et al. Visualizing nerve injury in a neuropathic pain model with [18F]FTC-146 PET/MRI. *Theranostics*. 2017;7(11):2794–2805.
3. James ML, Shen B, Nielsen CH, et al. Evaluation of σ1 receptor radioligand 18F-FTC-146 in rats and squirrel monkeys using PET. *J Nucl Med*. 2014;55(1):147–153.
4. Shen B, James ML, Andrews L, et al. Further validation to support clinical translation of [18F]FTC-146 for imaging sigma-1 receptors. *EJNMMI Res*. 2015;5(1):49.
5. Hjørnevik T, Cipriano PW, Shen B, et al. Biodistribution and radiation dosimetry of 18F-FTC-146 in humans. *J Nucl Med*. 2017;58(12):2004–2009.
6. Hill JA, Martin WR, Milgram JW. Unusual arthroscopic knee lesions: case report of an intra-articular lipoma. *J Natl Med Assoc*. 1993;85(9):697–699.
7. Hirasawa Y, Okajima S, Ohta M, Tokioka T. Nerve distribution to the human knee joint: anatomical and immunohistochemical study. *Int Orthop*. 2000;24(1):1–4.
8. Monnet FP. Sigma-1 receptor as regulator of neuronal intracellular Ca2+: clinical and therapeutic relevance. *Biol Cell*. 2005;97(12):873–883.
9. Tejada MA, Montilla-García A, Sánchez-Fernández C, et al. Sigma-1 receptor inhibition reverses acute inflammatory hyperalgesia in mice: role of peripheral sigma-1 receptors. *Psychopharmacology*. 2014;231(19):3855–3869.
